Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib

Mizuno, H; Nakayama, T; Miyata, Y; Saito, S; Nishiwaki, S; Nakao, N; Takeshita, K; Naoe, T
October 2012
Leukemia (08876924);Oct2012, Vol. 26 Issue 10, p2269
Academic Journal
Hodgkin's lymphoma is frequently associated with mast cell infiltration that correlates directly with disease severity, but the mechanisms underlying this relationship remain unclear. Here, we report that mast cells promote the growth of Hodgkin's tumor by modifying the tumor microenvironment. A transplantation assay shows that primary murine mast cells accelerate tumor growth by established Hodgkin's cell lines, and promote marked neovascularization and fibrosis. Both mast cells and Hodgkin's cells were sensitive to bortezomib, but mast cells were more resistant to bortezomib. However, bortezomib inhibited degranulation, PGE2-induced rapid release of CCL2, and continuous release of vascular endothelial growth factor-A from mast cells even at the concentration that did not induce cell death. Bortezomib-treated mast cells lost the ability to induce neovasculization and fibrosis, and did not promote the growth of Hodgkin tumor in vivo. These results provide further evidence supporting causal relationships between inflammation and tumor growth, and demonstrate that bortezomib can target the tumor microenvironment.


Related Articles

  • SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells. Wei, Jing-Jing; Song, Chuan-Wang; Sun, Ling-Cong; Yuan, Ye; Li, Dong; Yan, Bin; Liao, Sheng-Jun; Zhu, Jian-Hua; Wang, Qi; Zhang, Gui-Mei; Feng, Zuo-Hua // Cancer Immunology, Immunotherapy;Mar2012, Vol. 61 Issue 3, p303 

    Mast cells may have either antitumor or tumor-promoting potential. Nevertheless, mast cells in tumor microenvironment have been found to promote tumor growth. So far the mechanisms underlying the modulation of mast cell function in tumor microenvironment remains to be fully elucidated. Here, we...

  • Investigation of Antiangiogenic Tumor Therapy Potential of Microencapsulated HEK293 VEGF165b Producing Cells. Afkhami, Fatemeh; Durocher, Yves; Prakash, Satya // Journal of Biomedicine & Biotechnology;2010, p1 

    To investigate the antiangiogenic potential of encapsulated VEGF165b producing HEK293 cells, Human Embryonic Kidney 293 (HEK293) cells were stably transfected to produce VEGF165b. Then they were encapsulated in alginate - polylysine -alginate (APA) microcapsules. VEGF165b productivity and...

  • Tpl2 Inhibitors Thwart Endothelial Cell Function in Angiogenesis and Peritoneal Dissemination. Wen-Jane Lee; Keng-Hsin Lan; Chiang-Ting Chou; Yu-Chiao Yi; Wei-Chih Chen; Hung-Chuan Pan; Yen-Chun Peng; Keh-Bin Wang; Yi-Ching Chen; Te-Hsin Chao; Hsing-Ru Tien; Wayne Huey Herng Sheu; Meei-Ling Sheu // Neoplasia;Sep2013, Vol. 15 Issue 9, p1036 

    Angiogenesis is critical in the development of cancer, which involves several angiogenic factors in its peritoneal dissemination. The role of protein tumor progression locus 2 (Tpl2) in angiogenic factor--related endothelial cell angiogenesis is still unclear. To understand the precise...

  • Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases. Grimm, Daniela; Bauer, Johann; Schoenberger, Johann // Current Vascular Pharmacology;Jul2009, Vol. 7 Issue 3, p347 

    Neoangiogenesis, the development of new blood vessels from a pre-existing vasculature involves the migration behavior, proliferation and differentiation of endothelial cells. This process is an important aspect to both the growth and metastasis of solid tumors. In growing tumors, the development...

  • VEGF EXPRESSION AND MICROVESSEL DENSITY IN GASTRIC CARCINOMAS. Stanculescu, Diana; Simionescu, Cristiana; Georgescu, Claudia; Margaritescu, Cl.; Muntean, Mihaela // Annals of the Romanian Society for Cell Biology;2011, Vol. 16 Issue 2, p188 

    The angiogenesis is one of the most important factors in tumor development and dissemination. We aimed to evaluate the angiogenesis and its involvement in gastric carcinomas natural history, based on immunohistochemical expression of vascular endothelial growth factor and tumor microvessel...

  • AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Watanabe, M.; Boyer, J. L.; Crystal, R. G. // Gene Therapy;Aug2010, Vol. 17 Issue 8, p1042 

    Vascular endothelial growth factor (VEGF) produced by tumor cells has a central role in stimulating angiogenesis required for tumor growth. Humanized monoclonal anti-VEGF antibody (bevacizumab, Avastin), approved as a treatment for non-squamous, non-small cell lung cancer, requires...

  • Host CD73 impairs anti-tumor immunity. Salmi, Marko; Jalkanen, Sirpa // OncoImmunology;Mar/Apr2012, Vol. 1 Issue 2, p247 

    The enzymatic activity of CD73 produces immune-suppressing adenosine. In CD73 deficient hosts, tumor growth and tumor infiltration by Tregs and type 2 immunosuppressive macrophages is reduced. Pharmacological inhibition of CD73 in wild-type mice has similar tumor-suppressing effects. Host CD73...

  • Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. Ying Gao; Na Lu; Yun Ling; Yan Chen; Ling Wang; Qing Zhao; Qi Qi; Wei Liu; Haiwei Zhang; Qidong You; Qinglong Guo // Journal of Cancer Research & Clinical Oncology;May2010, Vol. 136 Issue 5, p667 

    In this study, we examined the antiangiogenic effect of oroxylin A in vitro and in vivo and explored the potential mechanisms for this effect. Transwell assay and tube formation assay were used to evaluate the effects of oroxylin A on vascular endothelial growth factor (VEGF)-induced migration...

  • Oncology Nursing in a New Era: Optimizing Treatment With Bevacizumab. Marrs, Joyce; Zubal, Beth A. // Clinical Journal of Oncology Nursing;Oct2009, Vol. 13 Issue 5, p564 

    Overexpression of vascular endothelial growth factor (VEGF) by tumor cells promotes angiogenesis, which correlates with progressive tumor growth and poor outcomes in many types of cancer. Bevacizumab inhibits VEGF to promote regression of tumor vessels by limiting blood supply and tumor growth,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics